Comment on FDA's Breakthrough Therapy Designation of Intranasal Esketamine for the Treatment of Major Depressive Disorder with Imminent Risk of Suicide
{"title":"Comment on FDA's Breakthrough Therapy Designation of Intranasal Esketamine for the Treatment of Major Depressive Disorder with Imminent Risk of Suicide","authors":"Rejish K Thomas, M. Cetin, G. Baker, S. Dursun","doi":"10.5455/BCP.20161027122045","DOIUrl":null,"url":null,"abstract":"","PeriodicalId":17852,"journal":{"name":"Klinik Psikofarmakoloji Bulteni-bulletin of Clinical Psychopharmacology","volume":null,"pages":null},"PeriodicalIF":0.0000,"publicationDate":"2016-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"6","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Klinik Psikofarmakoloji Bulteni-bulletin of Clinical Psychopharmacology","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.5455/BCP.20161027122045","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q","JCRName":"Medicine","Score":null,"Total":0}